Detection of tumor necrosis factor α but not tumor necrosis factor β in rheumatoid arthritis synovial fluid and serum
✍ Scribed by T. Saxne; M. A. Palladino Jr; D. Heinegãrd; N. Talal; F. A. Wollheim
- Publisher
- John Wiley and Sons
- Year
- 1988
- Tongue
- English
- Weight
- 386 KB
- Volume
- 31
- Category
- Article
- ISSN
- 0004-3591
No coin nor oath required. For personal study only.
✦ Synopsis
Synovial fluids from 6 of 12 patients with rheumatoid arthritis (RA) and from 3 of 11 patients with reactive arthritis contained measurable levels of tumor necrosis factor a (TNFa). Seven of 12 sera from RA patients contained TNFa, while only 1 of those from reactive arthritis patients was positive. Gamma-interferon was detected in the synovial fluids and sera of only the RA patients. Tumor necrosis factor /3 was not detected in any sera or synovial fluids. RA patients with detectable TNFa had higher erythrocyte sedimentation rates and synovial fluid leukocyte counts.
In some cases, inflammatory joint disease may result in erosive destruction of cartilage and bone, whereas in other cases, the process may heal and leave the joint structures intact. The basic pathogenetic differences between destructive rheumatoid arthritis (RA) and nondestructive reactive arthritis are not
📜 SIMILAR VOLUMES
COPD ϭ chronic obstructive pulmonary disease. 300 Letters \* RA ϭ rheumatoid arthritis; JRA ϭ juvenile rheumatoid arthritis; ESR ϭ erythrocyte sedimentation rate; CRP ϭ C-reactive protein; VAS ϭ visual analog scale; GH ϭ general health; DAS28 ϭ Disease Activity Score in 28 joints; HAQ ϭ Health Asses
## Abstract ## Objective Treatment of rheumatoid arthritis (RA) with tumor necrosis factor (TNF)–blocking agents, including etanercept and infliximab, has resulted in reductions in the radiographic progression of RA. However, the exact mechanism by which this protection occurs has not been determi